FDA

Updated daily, the FDA calendar gives you insight into FDA actions on companies and upcoming actions the FDA is expected to take. Benzinga's FDA calendar shows historical FDA data, upcoming dates that companies will be impacted by the FDA and ranges of dates.

Get Alert
NUVB
NUVBNuvation Bio Inc.
Safusidenib
Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology
Phase 2————11/16/2026
8:00 AM
Follow-up data

Nuvation Bio Inc. announced new long-term follow-up data from the Phase 2 (J201) study of investigational safusidenib in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant glioma.

View Source →
Get Alert
MDWD
MDWDMediWound Ltd
EscharEx
Chronic Wounds
—————11/16/2026
8:00 AM
Provided Update

MediWound Ltd. announced that it will host a virtual Key Opinion Leader (KOL) event on Wednesday, December 2, 2026, at 11:00 a.m. Eastern Time.

View Source →
Get Alert
BTAI
BTAIBioXcel Therapeutics Inc
IGALMI™
Sublingual film
—————11/16/2026
8:00 AM
FDA Approval

Teva Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) approval of IGALMI (dexmedetomidine) sublingual film for at-home use.

View Source →
Get Alert
PIVOT-006
In patients with intermediate-risk non-muscle invasive bladder cancer (IR NMIBC).
—————11/16/2026
8:00 AM
Top-line results

CG Oncology, Inc announced positive topline results from PIVOT-006, its Phase 3 registrational trial evaluating adjuvant intravesical cretostimogene grenadenorepvec in patients with intermediate-risk and high-grade Ta ≤3 cm NMIBC, following complete tumor resection.

View Source →
Get Alert
ESLA
ESLAEstrella Immunopharma Inc
ARTEMIS T
for cancer and autoimmune diseases
—————11/16/2026
8:00 AM
Findings Update

Estrella Immunopharma, Inc. today highlighted preclinical findings from an abstract accepted for poster presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 12–15, 2026, in New Orleans, Louisiana.

View Source →
Get Alert
CRBP
CRBPCorbus Pharmaceuticals Holdings Inc
CRB-913
For Obesity
—————11/16/2026
8:00 AM
Additional data

Corbus Pharmaceuticals Holdings, Inc announced today that additional data from the CANYON-1 Phase 1b obesity study were presented in a poster at ObesityWeek® 2026.

View Source →
Get Alert
BIVI
BIVIBioVie Inc
Bezisterim
For Parkinson's Disease Patients
Phase 2————11/16/2026
8:00 AM
Findings Update

BioVie Inc. announced new clinical and biomarker findings from the Phase 2 ADDRESS-LC trial of bezisterim were presented November 13, 2026, at the 4th Long COVID International Conference in Nice, France.

View Source →
Get Alert
RADX
RADXRadiopharm Theranostics
RAD101
patients with indeterminate brain metastases following radiotherapy.
Phase 2b————11/16/2026
8:00 AM
Data

Radiopharm Theranostics announced that data from the Phase 2b imaging study of RAD101 in suspected recurrent brain metastases following radiotherapy were presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting, which took place from November 12-15, 2026 in Philadelphia, PA.

View Source →
Get Alert
INAB
INABIN8bio Inc.
INB-200
For the treatment of newly diagnosed GBM solid tumors.
—————11/16/2026
8:00 AM
Updated data

IN8bio, Inc announced updated clinical data from its INB-200 and INB-400 programs in newly diagnosed glioblastoma (GBM), presented in an oral session at the 2026 Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia.

View Source →
Get Alert
ALRNAileron Therapeutics Inc
RNTX
RNTXRein Therapeutics
LTI-03
In Idiopathic Pulmonary Fibrosis
Phase 2————11/16/2026
7:30 AM
Observations

Rein Therapeutics announced preliminary blinded twelve-week observations from the ongoing RENEW Phase 2 trial evaluating its lead drug candidate, LTI-03, in patients with idiopathic pulmonary fibrosis (IPF).

View Source →
Get Alert
CMND-100
For Treatment Of AUD
Phase 1/2a————11/16/2026
7:30 AM
Enrollment Update

Clearmind Medicine Inc. announced the successful completion of patient enrollment for Part C of its ongoing Phase I/IIa clinical trial evaluating CMND-100.

View Source →
Get Alert
BLRX
BLRXBioLineRx Ltd
GLIX1
treatment of recurrent and progressive glioblastoma
—————11/16/2026
7:00 AM
Presentation

BioLineRx Ltd. announced that two posters featuring GLIX1 were presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting.

View Source →
Get Alert
CRDF
CRDFCardiff Oncology Inc
onvansertib
in Chronic Myelomonocytic Leukemia
Fast Track Designation————11/16/2026
7:00 AM
Designation Grant

Cardiff Oncology, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to onvansertib in combination with FOLFIRI/bevacizumab (bev) for the first-line treatment of adult patients with KRAS- or NRAS-mutated metastatic colorectal cancer (mCRC).

View Source →
Get Alert
LX2020
For PKP2 Arrhythmogenic Cardiomyopathy
Phase 1/2————11/16/2026
7:00 AM
Interim Data

Lexeo Therapeutics, Inc. announced positive interim data from the ongoing HEROIC-PKP2 Phase I/II clinical trial of LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM).

View Source →
Get Alert
HELP
HELPHelus Pharma™
HLP003
adjunctive treatment of major depressive disorder ("MDD")
Phase 3————11/16/2026
7:00 AM
Top-line results

Helus Pharma Inc. announced positive topline results from APPROACH, its Phase 3 pivotal study evaluating HLP003 (deuterated psilocin), as an adjunctive treatment for adults with major depressive disorder ("MDD").

View Source →
Get Alert
DurAVR® Transcatheter Heart Valve
in patients with severe calcific aortic stenosis
—————11/16/2026
6:00 AM
Presentation

Anteris Technologies Global Corp. announced that Rishi Puri, MD, PhD, Cleveland Clinic, will present one-year clinical and hemodynamic outcomes for the DurAVR® Transcatheter Heart Valve (THV) in a late-breaking session at PCR London Valves, held November 22–24, 2026, in London, United Kingdom.

View Source →
Get Alert
CYTK
CYTKCytokinetics Inc
Aficamten
Symptomatic obstructive hypertrophic cardiomyopathy (oHCM)
supplemental New Drug Application (sNDA)————11/16/2026
4:00 AM
FDA approved

Cytokinetics, Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) updating the U.S. Prescribing Information for MYQORZO® (aficamten) to include data from MAPLE-HCM, the Phase 3 trial comparing MYQORZO and the standard-of-care beta-blocker metoprolol, each as monotherapy, in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

View Source →
Get Alert
ACRS
ACRSAclaris Therapeutics Inc
ATI-2138
For the Treatment of Moderate to Severe Atopic Dermatitis
Phase 2b————11/16/2026
3:30 AM
Initiation

Aclaris Therapeutics, Inc. announced initiation of its randomized, double-blind, placebo-controlled Phase 2b ALPHA trial of modzatinib (ATI-2138) in patients with moderate-to-severe lichen planus (LP); the first cohort to be enrolled will be patients with oral erosive lichen planus (OLP).

View Source →
Get Alert
ACRS
ACRSAclaris Therapeutics Inc
ATI-045
In Atopic Dermatitis (AD)
Phase 2————11/16/2026
3:28 AM
Top-line results

Aclaris Therapeutics, Inc. announced top line results from the Phase 2 ADMIRATION trial that evaluated the efficacy and safety of bosakitug (ATI-045), a humanized anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, in patients with moderate-to-severe atopic dermatitis.

View Source →
Get Alert
Privosegtor
For Vision Loss
Investigational New Drug (IND)————11/16/2026
2:00 AM
FDA Clearance

Oculis Holding AG announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for Privosegtor for the treatment of acute multiple sclerosis (MS) relapses.

View Source →
Get Alert

Recent FDA Approvals